Pharmaceutical salts have traditionally been used to address formulation issues, including low solubility. Preliminary in vitro and in vivo studies indicate that lipophilic salt forms can be enabling for lipid formulations by supporting substantially higher drug loadings—more than 10-fold in some cases—and better solubilization than would be possible using free drug alone. Through the use of lipophilic salt forms, formulators can capitalize on the well-established benefits of lipid formulations (e.g., by overcoming product design constraints like the number and/or size of dosage units required). This webinar describes an approach used to prepare lipophilic salt forms for a range of APIs and formulate these salts in concentrated lipid formulations ready for oral delivery.
Please note that Lonza has updated its Privacy Policy. By visiting our website or using services provided by Lonza, you are accepting the practices described in the Privacy Policy.
We also use cookies on our websites. Cookies allow us to give you the best browsing experience and help us to understand how you use our site. You can disable cookies but parts of our website may not work. Please read our updated Cookies Policy for information about which cookies we use and the information we collect. By continuing to use this website, you agree that we may store and access cookies on your device.
By clicking "I Agree", you confirm that you are above the age of 16, that you have read and understood the Privacy Policy and the Cookies Policy, and that you agree to the collection, use and processing of your Personal Information by Lonza in accordance with said policies.